Nivolumab Combinations to be Explored in NSCLC
October 7th 2014Several clinical trials combining nivolumab (Opdivo) with targeted therapies against ALK, c-MET, and T790M for patients with non-small cell lung cancer (NSCLC) have been established as part of a collaboration between Novartis and Bristol-Myers Squibb (BMS).
Eltrombopag for Severe Aplastic Anemia Approved by FDA
August 27th 2014The FDA has approved eltrombopag (Promacta) as a treatment for patients with severe aplastic anemia (SAA) following an insufficient response to immunosuppressive therapy, based on data from an open-label, single-arm phase II trial.
Bevacizumab for Advanced Cervical Cancer Approved by FDA
August 15th 2014The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer, based on the improvement in OS in the phase III GOG 240 study.
Significant OS Benefit Seen With TAS-102 Monotherapy in Refractory mCRC
August 13th 2014Significantly extended overall survival (OS) and progression-free survival (PFS) was seen with oral nucleoside TAS-102 treatment in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Extended Adjuvant Treatment With Neratinib Improves DFS in Breast Cancer
July 24th 2014Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab.
Vemurafenib- Cobimetinib Combo Improves PFS in Phase III Melanoma Trial
July 14th 2014The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.
First FDA Breakthrough Designation Granted to CAR Therapy
July 11th 2014The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).